Multiple myeloma (MM) treatment has consistently evolved and, particularly, for R/R patients, the treatment with CAR-T cells targeting the B cell receptor-maturation antigen (BCMA) was successfully introduced. Here, TNFRSF17 is linked to plasma cell myeloma.